pazopanib

pazopanib

美 　英

• 网络帕唑帕尼；盐酸帕唑帕尼；帕唑帕尼片

例句

The preclinical and clinical researches have demonstrated that pazopanib has potent antitumor effects and is well tolerated.

该药在临床前和临床研究中表现出了较强的抗肿瘤活性，且耐受性较好。

Pazopanib was evaluated in a placebo-controlled Phase 3 study involving 435 patients with renal cell carcinoma.

帕唑帕尼进行了评估，安慰剂控制的第三期涉及435例肾细胞癌患者的研究。

Patients were randomized (2: 1) to receive pazopanib 800mg or placebo once daily.

患者被随机（2：1）接受800毫克或安慰剂帕唑帕尼每日一次。

In this trial, the overall median progression free survival (PFS) was 9. 2 months with pazopanib and 4. 2 months with placebo.

在这个试验中，整体无进展生存期（PFS）为9.2和4.2个月，帕唑帕尼与安慰剂个月。

Treatment-naive patients who received pazopanib experienced 11. 1 months of median PFS vs 2. 8 months with placebo.

治疗初治患者谁收到帕唑帕尼经验的中位PFS11.1个月比2.8个月的安慰剂。